Analyst Yigal Nochomovitz from Citi maintained a Buy rating on Neurocrine and keeping the price target at $203.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Yigal Nochomovitz has given his Buy rating due to a combination of factors that highlight Neurocrine’s strong market position and growth potential. The recent announcement regarding TEVA’s Austedo/Austedo XR pricing was in line with expectations, which alleviates concerns over pricing pressures on Neurocrine’s Ingrezza. This stability in pricing allows Neurocrine greater flexibility in setting competitive prices through rebates.
Additionally, Neurocrine’s strategic initiatives, such as expanding their salesforce and enhancing contracting efforts to boost formulary coverage, are expected to maintain Ingrezza’s competitive edge in the market. These actions are projected to drive steady new patient starts, contributing to a positive outlook for the company’s stock, which is reflected in the expected share price return of 41.4%.
Nochomovitz covers the Healthcare sector, focusing on stocks such as Neurocrine, Zymeworks, and Arcus Biosciences. According to TipRanks, Nochomovitz has an average return of 4.7% and a 39.51% success rate on recommended stocks.
In another report released on November 19, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $157.00 price target.